Covid-19: WHO panel set to decide on emergency use of Chinese vaccine

A key World Health Organisation panel was set to decide whether to authorise the emergency use of a Chinese-made Covid-19 vaccine

Covid-19: WHO panel set to decide on emergency use of Chinese vaccine
AP Geneva
2 min read Last Updated : May 07 2021 | 8:06 PM IST

A key World Health Organisation panel was set to decide Friday whether to authorize emergency of a Chinese-made COVID-19 vaccine, a WHO spokesperson said, potentially paving the way for millions of doses to reach needy countries through a U.N.-backed program.

The review by a technical advisory group could open the possibility of the Sinopharm vaccine being included in the UN-backed COVAX programme in the coming weeks or months, and distributed through WHO's regional office for the Americas and the UN children's agency UNICEF.

WHO spokesman Christian Lindmeier said a decision was expected later Friday.

Apart from efficacy information, Sinopharm has released very little public data about its two vaccines - one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.

The Beijing shot is one that WHO is considering for an emergency use listing.

A separate group advising the UN agency on vaccines said it was very confident the Sinopharm vaccine protects people ages 18-59. The group said it had a low level of confidence of vaccine's efficacy in people 60 and over. It expressed very low confidence in the available data about potentially serious side effects in that age group.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusWHOWorld Health OrganisationCoronavirus Vaccine

First Published: May 07 2021 | 7:49 PM IST

Next Story